Insulin Lispro Sanofi

Insulin Lispro, the active ingredient in Insulin Lispro Sanofi, is a rapid‑acting insulin analog presented as a solution for subcutaneous and intravenous use. It treats hyperglycaemia in patients with type 1 and type 2 diabetes mellitus. GNH USA supplies Insulin Lispro Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Lispro Sanofi is a rapid‑acting insulin analogue used in the management of diabetes mellitus by providing post‑prandial glucose control.

Diabetes mellitus type 1: improves post‑meal glucose levels and reduces hyperglycaemia. Diabetes mellitus type 2: complements basal insulin or oral agents to achieve target glycaemic control. Gestational diabetes (off‑label): may be considered when other therapies are insufficient, under specialist supervision.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilisation. - Lipodystrophy: localized fat tissue changes with repeated injections. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypoglycaemia: can lead to loss of consciousness, seizures, or injury. - Anaphylactic reaction: life‑threatening allergic response with rash, swelling, or breathing difficulty. - Angioedema: rapid swelling of face, lips, or tongue. - Serum sickness‑like reaction: fever, rash, arthralgia. - Hypokalemia: low potassium levels, especially with high insulin doses. - Ketoacidosis (if insulin omitted): metabolic emergency requiring urgent care.

Before using Insulin Lispro Sanofi, consider the following precautions: - Dose adjustment: individualise dosing based on blood glucose monitoring and carbohydrate intake. - Renal impairment: monitor closely as insulin clearance may be reduced. - Hepatic impairment: use with caution; altered glucose metabolism may occur. - Pregnancy and lactation: discuss potential risks and benefits with a healthcare professional. - Hypoglycaemia risk: educate patients on recognising and treating low blood glucose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, requiring careful monitoring. - Sulfonylureas or meglitinides: increase risk of severe hypoglycaemia when combined. - Glucagon: concurrent use can cause unpredictable glucose responses.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may potentiate insulin’s glucose‑lowering effect. - Thiazide diuretics: can raise blood glucose, necessitating dose adjustments. - Oral contraceptives: may affect insulin sensitivity and glucose control. - Corticosteroids: can increase insulin requirements. - Alcohol: may potentiate hypoglycaemia, especially with delayed meals.